Global CRISPR/CAS 9 Technology Market Size to Reach USD 13,072.73 Million in 2032 |Emergen Research

Vancouver, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The global CRISPR/CAS 9 technology market size is expected to reach USD 13,072.73 Million at a steady revenue CAGR of 20.4% in 2032, according to latest analysis by Emergen Research. Steady CRISPR/CAS 9 market revenue growth is due to ability for researchers and experts to use the technology to correct genetic defects, yield better crop varieties, and treat human diseases.

CAS 9 is an enzyme that acts as a pair of molecular scissors and can cut two strands of DNA at a specific location in the genome so that bits of DNA can be added or removed. Technological advancements in CRISPR/CAS 9 has revolutionized areas of cancer research and treatment. Currently, it has become mainstream methodology in cancer biology studies. In April 2021, the U.S. FDA approved clinical trial testing for CRISPR-based gene therapy product, which have been designed to treat genetic defects that can lead to sickle cell disease. Scientists at UC San Francisco (UCSF), UC Berkeley, and UC Los Angeles (UCLA) have received U.S. Food and Drug Administration approval to jointly launch an early phase, first-in-human clinical trial of a CRISPR gene correction therapy in patients with sickle cell disease using the patient’s own blood-forming stem cells.

Receive the FREE Sample Report of CRISPR/CAS 9 Technology Market Research Insights @ https://www.emergenresearch.com/request-sample/768

Moreover, development of CRISPR-based diagnostic tests to address sample collection and timeline challenges for screening of COVID-19 is driving market growth. The tests are designed to provide various advantages such as high sensitivity and precision, portability, and rapid detection. In March 2020, New York genome center researchers developed new CRISPR screening technology to target RNA, including RNA of COVID-19 virus. 

However, lack of international regulatory framework for gene editing products is hampering market revenue growth. Countries are evaluating to what extent are the current regulations adequate for research conducted with gene editing.

Scope of Research

Click to Purchase this Report at an Exclusively Discounted Rate @ https://www.emergenresearch.com/request-discount/768

MAJOR COMPANIES and Competitive Landscape

The global CRISPR/CAS 9 technology market is consolidated, with few small- and medium-sized players accounting for majority revenue share. Established companies are engaged in various research and development activities and initiatives to develop and deploy new and more efficient product and services in the CRISPR/CAS 9 technology market. Some major players operating in the market are:

• Boston Merck KGaA
• AstraZeneca PLC
• GenScript
• eGenesis
• Caribou Biosciences, Inc.
• Horizon Discovery Group plc
• Lonza
• Thermo Fisher Scientific, Inc.
• Hera BioLabs
• Takara Bio Inc.

Strategic Development

• In June 2021, QIAGEN launched dedicated CRISPR products for simplified and rapid analysis of gene editing experiments. QIAGEN’s QIAprep&amp CRISPR Kit and CRISPR Q-Primer Solutions allow researchers to analyze edited genetic material at rapid speed and efficiency to determine how their interventions have changed functions of DNA sequence.
• In May 2021, ERS Genomics Limited and GenScript Biotech Corporation announced signing of a non-exclusive agreement granting the latter access to ERS Genomics’ CRISPR/Cas9 patent portfolio. ERS was formed to provide access to foundational CRISPR/Cas9 intellectual property that is co-owned by GenScript Biotech Corporation and Dr. Emmanuelle Charpentier. The agreement will enhance GenScript’s CRISPR offering for gene and cell therapy research.

Direct Order Can Be Placed Through This Link [Exclusive Copy] @ https://www.emergenresearch.com/select-license/768

Some Key Highlights From the Report

• In June 2021, QIAGEN launched dedicated CRISPR products for simplified and rapid analysis of gene editing experiments. QIAGEN’s QIAprep&amp CRISPR Kit and CRISPR Q-Primer Solutions allow researchers to analyze edited genetic material with rapid speed and efficiency to determine how their interventions have changed function of DNA sequence.
• Product segment accounted for larger revenue share in 2020 due to emergence of innovative tools and CRISPR CAS 9 gene editing kits. These products address several objectives such as genome engineering, genome cleavage, easy gene knockouts, and reduced off-target cutting.
• Genome engineering gives scientists the ability to change an organism’s DNA. CRISPR/CAS 9 is one of the approaches of genome editing as it is cheaper, faster and more accurate than the existing methods. Genome engineering is being used in research on a wide variety of diseases including hemophilia, cystic fibrosis, and sickle cell disease.
• Biotechnology & pharmaceutical companies segment accounted for largest revenue share in 2020 as pharmaceutical companies are rapidly adopting CRISPR/CAS 9 technology to develop improved biological models for human diseases in less time. Ongoing pipeline projects by major biotechnology & pharmaceutical companies is also expected to drive market revenue growth.
• Asia Pacific market revenue is expected to register a rapid rate during the forecast period due to high demand from China. CRISPR/CAS 9 is being utilized in China to delete genes in livestock which inhibit hair and muscle growth to grow larger stocks for the country’s commercial wool and meat industries. In the future, it could become a common way to expand livestock industries. The Chinese government awarded almost USD 3.5 million to 42 CRISPR projects.

For More Details On this Report @ https://www.emergenresearch.com/industry-report/crispr-cas-9-technology-market

Emergen Research has segmented the global CRISPR/CAS 9 technology market on the basis of product & service, application, end-use, and region:

• Product & Service Outlook (Revenue, USD Million; 2019–2032)
  • By Product
    1. Kits & Enzymes
       • Vector-based Cas
       • DNA-free Cas
    2. Libraries
    3. Design Tool
    4. Antibodies
    5. Others
  • By Service
    1. Cell Line Engineering
    2. gRNA Design
    3. Microbial Gene Editing
    4. DNA Synthesis
• Application Outlook (Revenue, USD Million; 2019–2032)
  • Biomedical
    1. Genome Engineering
    2. Disease Model Studies
    3. Functional Genomics
    4. Epigenetics
    5. Others
  • Agricultural
• End-use Outlook (Revenue, USD Million; 2019–2032)
  • Biotechnology & Pharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Academics & Government Research Institutes
• Regional Outlook (Revenue, USD Million; 2019–2032)
  • North America
    1. U.S.
    2. Canada
    3. Mexico
  • Europe
    1. Germany
    2. U.K.
    3. France
    4. Spain
    5. BENELUX
    6. Rest of Europe
  • Asia Pacific
    1. China
    2. India
    3. Japan
    4. South Korea
    5. Rest of APAC
  • Latin America
    1. Brazil
    2. Rest of LATAM
  • Middle East & Africa
    1. Saudi Arabia
    2. UAE
    3. Israel
    4. Rest Of MEA

Curated Reports You Shouldn't Miss: Dive In Now!

Molecular Diagnostics Point of Care Market By Test Location (PoC, OTC), By Technology (PCR-based, Hybridization-based, Others), By Application (Oncology, Hematology, Others) and By End-Use (Decentralized Labs, Hospitals, Others), Forecasts to 2027

NGS Sample Preparation Market By Workflow (NGS Library Preparation Kits, Semi-automated Library Preparation, Others), By Application (Oncology, Clinical Investigation, Others), and By End-User (Academic, Clinical, Others), Forecasts to 2027

Nucleic Acid Isolation and Purification Market, By Product (Kits and Reagents, Instruments), Isolation & purification type (DNA, RNA), By Application, By Method, By End User, and By Region Forecast to 2030

Viral Vector and Plasmid Manufacturing Market, By Vector Type (Plasmid DNA, AAV), By Disease Type (Cancer, Genetic Disorder), By Application (Gene Therapy, Cell Therapy), By End-Use, and By Region Forecast to 2030

Healthcare Interoperability Solutions Market, By Interoperability Level (Foundational Interoperability, Structural Interoperability, Semantic Interoperability), By Type (Software Solutions, Services), By End-use, and By Region Forecast to 2032

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: https://www.emergenresearch.com/

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Explore Our Japanese Version: CRISPR/CAS 9 Technology Market

Explore Our Blogs and Insights Section: https://www.emergenresearch.com/insights

Read our Press Release @ https://www.emergenresearch.com/press-release/global-crispr-cas-9-technology-market